Risk of mycobacterial infections associated with rheumatoid arthritis in Ontario, Canada

Chest

Volumn 146, Issue 3, 2014, Pages 563-572

  Brode, Sarah K ^a,c,d   Jamieson, Frances B ^d,f   Ng, Ryan ^g   Campitelli, Michael A ^g   Kwong, Jeffrey C ^b,d,f,g   Paterson, J Michael ^e,g,h   Li, Ping ^g   Marchand Austin, Alexandre ^f   Bombardier, Claire ^e,i   Marras, Theodore K ^a,d  

^a Joint Division of Respirology   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c West Park Healthcare Centre   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f PUBLIC HEALTH ONTARIO   (Canada)

^g INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; ASTHMA; ATYPICAL MYCOBACTERIOSIS; CANADA; CANADIAN; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE TRANSMISSION; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOBACTERIOSIS; MYCOBACTERIUM GORDONAE; POPULATION RESEARCH; PREDICTIVE VALUE; PREVALENCE; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; AGED; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; COMPLICATION; EPIDEMIOLOGY; MIDDLE AGED; MYCOBACTERIUM INFECTIONS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; ONTARIO; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84907201015     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-2058     Document Type: Article

References (49)

1. American Thoracic Society; CDC; Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep. 2003; 52 (RR-11): 1-77.
2. Al Houqani M, Jamieson F, Chedore P, Mehta M, May K, Marras TK. Isolation prevalence of pulmonary nontuberculous mycobacteria in Ontario in 2007. Can Respir J. 2011; 18 (1): 19-24.
3. Al-Houqani M, Jamieson F, Mehta M, Chedore P, May K, Marras TK. Aging, COPD, and other risk factors do not explain the increased prevalence of pulmonary Mycobacterium avium complex in Ontario. Chest. 2012; 141 (1): 190-197.
4. Mehta M, Marras TK. Impaired healthrelated quality of life in pulmonary nontuberculous mycobacterial disease. Respir Med. 2011; 105 (11): 1718-1725.
5. Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest. 2004; 126 (2): 566-581.
6. Bykerk VP, Akhavan P, Hazlewood GS, et al; Canadian Rheumatology Association. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012; 39 (8): 1559-1582.
7. Brassard P, Lowe A-M, Bernatsky S, Kezouh A, Suissa S. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum. 2009; 61 (3): 300-304.
8. Yamada T, Nakajima A, Inoue E, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis. 2006; 65 (12): 1661-1663.
9. Seong S-S, Choi C-B, Woo J-H, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol. 2007; 34 (4): 706-711.
10. Carmona L, Hernández-García C, Vadillo C, et al; EMECAR Study Group. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol. 2003; 30 (7): 1436-1439.
11. Widdifield J, Bernatsky S, Paterson JM, et al. Accuracy of Canadian health administrative databases in identifying patients with rheumatoid arthritis: a validation study using the medical records of rheumatologists. Arthritis Care Res (Hoboken). 2013; 65 (10): 1582-1591.
12. Widdifield J, Bombardier C, Bernatsky S, et al. Accuracy of Canadian health administrative databases in identifying patients with rheumatoid arthritis using a random sample of 7500 patients seen in primary care. Arthritis Rheum. 2012; 64 (10): S402.
13. Arnow PM, Bakir M, Thompson K, Bova JL. Endemic contamination of clinical specimens by Mycobacterium gordonae. Clin Infect Dis. 2000; 31 (2): 472-476.
14. Andréjak C, Thomsen VO, Johansen IS, et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med. 2010; 181 (5): 514-521.
15. Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010; 182 (7): 970-976.
16. Marras TK, Mehta M, Chedore P, May K, Al Houqani M, Jamieson F. Nontuberculous mycobacterial lung infections in Ontario, Canada: clinical and microbiological characteristics. Lung. 2010; 188 (4): 289-299.
17. Winthrop KL, McNelley E, Kendall B, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med. 2010; 182 (7): 977-982.
18. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002; 25 (3): 512-516.
19. Antoniou T, Zagorski B, Loutfy MR, et al. Validation of case-fi nding algorithm derived from administrative data of identifying adults living with human immunodefi ciency virus infection. PLoS ONE. 2011; 6 (6): e21748.
20. Vlasschaert MEO, Bejaimal SAD, Hackam DG, et al. Validity of administrative database coding for kidney disease: a systematic review. Am J Kidney Dis. 2011; 57 (1): 29-43.
21. Lopushinsky SR, Covarrubia KA, Rabeneck L, Austin PC, Urbach DR. Accuracy of administrative health data for the diagnosis of upper gastrointestinal diseases. Surg Endosc. 2007; 21 (10): 1733-1737.
22. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying individuals with physician diagnosed COPD in health administrative databases. COPD. 2009; 6 (5): 388-394.
23. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying patients with physician-diagnosed asthma in health administrative databases. Can Respir J. 2009; 16 (6): 183-188.
24. Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a populationbased cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013; 65 (3): 353-361.
25. Kralj B. Measuring "rurality" for purposes of health-care planning: an empirical measure for Ontario. Ont Med Rev. 2000; 67 (10): 33-52.
26. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005; 52 (7): 1986-1992.
27. Winthrop KL, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis. 2013; 72 (1): 37-42.
28. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004; 50 (2): 372-379.
29. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare benefi ciaries. Am J Respir Crit Care Med. 2012; 185 (8): 881-886.
30. Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011; 63 (3): 633-639.
31. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med. 1998; 19 (4): 667-685.
32. Park S-W, Song JW, Shim TS, et al. Mycobacterial pulmonary infections in patients with idiopathic pulmonary fibrosis. J Korean Med Sci. 2012; 27 (8): 896-900.
33. van Ingen J, Hoefsloot W, Dekhuijzen PN, Boeree MJ, van Soolingen D. The changing pattern of clinical Mycobacterium avium isolation in the Netherlands. Int J Tuberc Lung Dis. 2010; 14 (9): 1176-1180.
34. Dixon WG, Hyrich KL, Watson KD, et al; BSRBR Control Centre Consortium; BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010; 69 (3): 522-528.
35. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. N Engl J Med. 2001; 345 (15): 1098-1104.
36. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis. 2006; 43 (6): 717-722.
37. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis. 2004; 39 (8): 1254-1255.
38. Tubach F, Salmon D, Ravaud P, et al; Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009; 60 (7): 1884-1894.
39. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to signifi cant increase in tuberculosis risk: a multicenter active-surveillance report. A rthritis Rheum. 2003; 48 (8): 2122-2127.
40. Raval A, Akhavan-Toyserkani G, Brinker A, Avigan M. Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med. 2007; 147 (10): 699-702.
41. Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci U S A. 2000; 97 (16): 9203-9208.
42. Au K, Reed G, Curtis JR, et al; CORRONA Investigators. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011; 70 (5): 785-791.
43. Popa C, Netea MG, Barrera P, et al. Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving shortterm infliximab therapy. Cytokine. 2005; 30 (2): 72-77.
44. Chan ED, Iseman MD. Slender, older women appear to be more susceptible to nontuberculous mycobacterial lung disease. Gend Med. 2010; 7 (1): 5-18.
45. Raso GM, Pacilio M, Esposito E, Coppola A, Di Carlo R, Meli R. Leptin potentiates IFN-gamma-induced expression of nitric oxide synthase and cyclo-oxygenase-2 in murine macrophage J774A.1. Br J Pharmacol. 2002; 137 (6): 799-804.
46. Kartalija M, Ovrutsky AR, Bryan CL, et al. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med. 2013; 187 (2): 197-205.
47. Maurya V, Vijayan VK, Shah A. Smoking and tuberculosis: an association overlooked. Int J Tuberc Lung Dis. 2002; 6 (11): 942-951.
48. Long R, Ellis E, eds. Canadian Tuberculosis Standards. 6th ed. Ottawa, Canada: Canadian Lung Association and Health Canada; 2007.
49. Winthrop KL, Baxter R, Liu L, et al. The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy. Pharmacoepidemiol Drug Saf. 2011; 20 (3): 229-235.